Table 1.
Patient demographics and baseline characteristics.
| Variable | All (N = 91) | Treatment naïve |
Relapsed or ≥second line |
||
|---|---|---|---|---|---|
| Bendamustine monotherapy (n = 10) | Bendamustine + rituximab combination therapy (n = 6) | Bendamustine monotherapy (n = 20) | Bendamustine + rituximab combination therapy (n = 55) | ||
| Median age at diagnosis (range), years | 69.6 (55.0–86.9) | 72.3 (63.5–83.4) | 72.9 (67.8–85.3) | 68.3 (58.9–79.5) | 68.89 (55.0–87.0) |
| Median age at beginning of first therapy (range), years | 75.1 (70.2–89.9) | 75.4 (71.1–83.5) | 74 (70.8–85.7) | 74.7 (70.5–89.2) | 75.5 (70.3–89.9) |
| Gender, n (%) | |||||
| Women | 33 (36.3) | 3 (30.0) | 4 (66.7) | 7 (35.0) | 19 (34.5) |
| Men | 58 (63.7) | 7 (70.0) | 2 (33.3) | 13 (65.0) | 36 (65.5) |
| Mean BMI at treatment baseline (SD) | 26.3 (4.4) | 27.2 (3.3) | 29.2 (5.7) | 24.9 (3.7) | 26.3 (4.5) |
| Rai stage at diagnosis, n (%) | |||||
| 0 | 7 (7.7) | 1 (10.0) | 0 | 4 (20.0) | 2 (3.6) |
| I | 24 (26.4) | 1 (10.0) | 3 (50.0) | 8 (40.0) | 12 (21.8) |
| II | 14 (15.4) | 0 | 0 | 2 (10.0) | 12 (21.8) |
| III | 7 (7.7) | 0 | 1 (16.7) | 1 (5.0) | 5 (9.1) |
| IV | 8 (8.8) | 0 | 0 | 2 (10.0) | 6 (10.9) |
| Unknown | 11 (12.1) | 0 | 2 (33.3) | 1 (5.0) | 8 (14.8) |
| Missing | 20 (22.0) | 8 (80.0) | 0 | 2 (10.0) | 10 (18.5) |
| ECOG score at initiation of first therapy, n (%) | |||||
| 0 | 42 (46.1) | 5 (50.0) | 5 (83.4) | 8 (40.0) | 24 (43.6) |
| 1 | 39 (42.9) | 3 (30.0) | 0 | 12 (60.0) | 24 (43.6) |
| 2 | 1 (1.0) | 0 | 0 | 0 | 1 (1.8) |
| Missing | 9 (10.0) | 2 (20.0) | 1 (16.6) | 0 | 6 (11.0) |
| B symptoms, n (%) | |||||
| Absent | 70 (76.9) | 8 (80.0) | 5 (83.3) | 16 (80.0) | 41 (74.5) |
| Present | 14 (15.4) | 1 (10.0) | 1 (16.7) | 3 (15.0) | 9 (16.4) |
| Missing | 7 (7.7) | 1 (10.0) | 0 | 1 (5.0) | 5 (9.1) |
| Most frequent comorbidities, n (%) | |||||
| Rheumatologic disease | 14 (15.4) | 1 (10.0) | 1 (16.6) | 3 (15.0) | 9 (16.4) |
| Chronic pulmonary disease | 12 (13.2) | 1 (10.0) | 0 | 2 (10.0) | 9 (16.4) |
| Diabetes | 9 (9.9) | 1 (10.0) | 1 (16.6) | 4 (20.0) | 3 (5.5) |
| Prior MI | 7 (7.7) | 2 (20.0) | 1 (16.6) | 1 (5.0) | 3 (5.5) |
| Ulcer disease | 6 (6.6) | 0 | 0 | 3 (15.0) | 3 (5.5) |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; MI, myocardial infarction; SD, standard deviation.